Thrombotic events

[키워드] absence ACAnticoagulants addition adjusted age Anticoagulant Anticoagulants Antithrombin Antithrombotic association ATAntithrombin BMIbody mass index body mass index case-control study changes in clinical picture Comorbidities Comorbidity comparable Computed tomography Confirmed COVID-19 infection contribute Corona Virus Disease COVID COVID-19 COVID-19 infection COVID-19 patient COVID-19 patients COVIDCorona Virus Disease Critical CTComputed Tomography D-dimer D-dimer level Deep venous thrombosis Diagnosis Direct oral anticoagulant disease DOACDirect Oral Anticoagulant DVTDeep Venous Thrombosis dysfunction evaluate Factor V Leiden factor VIII FEUFibrinogen Equivalent Fibrinogen Equivalent FII G20210AProthrombin mutation Final FV LeidenFactor V Leiden FVIII FVIIIFactor VIII genetic defect HBSHeparin Binding Site Heparin Binding Site individual Infection LMWHlow molecular weight heparin low molecular weight heparin Mild Odds ratio OROdds Ratio outcome parameter Patient patient group PCR/RFLPpolymerase chain reaction/restriction fragment length polymorphism PEPulmonary Embolism polymerase chain reaction/restriction fragment length polymorphism Prophylaxis Prothrombin mutation Pulmonary embolism receive Result risk risk of COVID-19 serious complication severe COVID-19 significantly significantly increased symptomatic thrombosis thrombotic thrombotic complication thrombotic event Thrombotic events Treatment Unusual Thrombosis UTUnusual Thrombosis Venous Thromboembolism vitamin K antagonist VKAVitamin K antagonist VTEVenous Thromboembolism was performed
[DOI] 10.1016/j.thromres.2022.08.020 [Article Type] Research article